Приказ основних података о документу

dc.creatorBecarević, Mirjana
dc.creatorIgnjatović, Svetlana
dc.creatorMajkić-Singh, Nada
dc.date.accessioned2019-09-02T11:27:14Z
dc.date.available2019-09-02T11:27:14Z
dc.date.issued2012
dc.identifier.issn1433-6510
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/1632
dc.description.abstractBackground: To investigate the association between clinical and serological features of patients with primary antiphospholipid syndrome (PAPS) and TNF-alpha, interleukin 6 (IL-6), and soluble IL-2 receptor (sIL-2R). Methods: ELISA was used for measurement of antibodies (Abs) and TNF-alpha, while IL-6 and sIL-2R were measured by chemiluminescence. Results: PAPS patients with pulmonary emboli showed positive correlation between IgM isotype of anti-annexin A5 antibodies and TNF-alpha (r = 0.894, p = 0.041) and IgM class of anticardiolipin antibodies and sIL-2R (r = 0.900, p = 0.037). In PAPS with cerebrovascular insults, positive correlation was noticed between TNF-alpha and IgG isotype of anticardiolipin (r = 0.624, p = 0.040) and anti-annexinA5 Abs (r = 0.768, p = 0.006). Conclusions: Isotype analysis of antiphospholipid and anti-annexin A5 Abs and investigation of their association with TNF-alpha is important for differentiation of PAPS patients that are prone to further deterioration of arterial and venous thromboses. (Clin. Lab. 2012;58:1079-1084. DOI: 10.7754/Clin.Lab.2012.110918)en
dc.publisherClin Lab Publ, Heidelberg
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175036/RS//
dc.rightsrestrictedAccess
dc.sourceClinical Laboratory
dc.subjectAnti-annexin A5 antibodiesen
dc.subjectinterleukin 6en
dc.subjectprimary antiphospholipid syndromeen
dc.subjectsoluble interleukin 2 receptoren
dc.subjectTNF-alphaen
dc.titleDeterioration of Thromboses in Primary Antiphospholipid Syndrome: TNF-alpha and Anti-Annexin A5 Antibodiesen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractБецаревић, Мирјана; Игњатовић, Светлана; Мајкић-Сингх, Нада;
dc.citation.volume58
dc.citation.issue9-10
dc.citation.spage1079
dc.citation.epage1084
dc.citation.other58(9-10): 1079-1084
dc.citation.rankM23
dc.identifier.wos000310560200027
dc.identifier.doi10.7754/Clin.Lab.2012.110918
dc.identifier.pmid23163128
dc.identifier.scopus2-s2.0-84868572676
dc.type.versionpublishedVersion


Документи

ДатотекеВеличинаФорматПреглед

Уз овај запис нема датотека.

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу